{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:13:49Z","timestamp":1763018029506,"version":"3.37.3"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:00:00Z","timestamp":1554940800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Banting and Best Diabetes Centre at the University of Toronto"},{"name":"University of Toronto Merit Award"},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007476","name":"Canadian Diabetes Association","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007476","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009881","name":"Juvenile Diabetes Research Foundation Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009881","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00125-019-4871-8","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T20:03:54Z","timestamp":1555013034000},"page":"1090-1093","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Molecular regulation of the renin\u2013angiotensin system by sodium\u2013glucose cotransporter 2 inhibition in type 1 diabetes mellitus"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2289-4837","authenticated-orcid":false,"given":"Chantal","family":"Kopecky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuliya","family":"Lytvyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Domenig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlies","family":"Antlanger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes J.","family":"Kovarik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher C.","family":"Kaltenecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Poglitsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce A.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry-Anne","family":"Rye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Z. I.","family":"Cherney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus D.","family":"S\u00e4emann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,11]]},"reference":[{"issue":"22","key":"4871_CR1","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"issue":"7","key":"4871_CR2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"issue":"4","key":"4871_CR3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323\u2013334. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1515920","journal-title":"N Engl J Med"},{"issue":"6","key":"4871_CR4","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1172\/JCI72271","volume":"124","author":"K Reidy","year":"2014","unstructured":"Reidy K, Kang HM, Hostetter T, Susztak K (2014) Molecular mechanisms of diabetic kidney disease. J Clin Invest 124(6):2333\u20132340. \n                    https:\/\/doi.org\/10.1172\/JCI72271","journal-title":"J Clin Invest"},{"issue":"5","key":"4871_CR5","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N et al (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129(5):587\u2013597. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.005081","journal-title":"Circulation"},{"issue":"10","key":"4871_CR6","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ (2016) Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134(10):752\u2013772. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021887","journal-title":"Circulation"},{"issue":"1","key":"4871_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/ki.2015.107","volume":"88","author":"LC Roksnoer","year":"2015","unstructured":"Roksnoer LC, van Veghel R, de Vries R et al (2015) Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats. Kidney Int 88(1):109\u2013120. \n                    https:\/\/doi.org\/10.1038\/ki.2015.107","journal-title":"Kidney Int"},{"issue":"5","key":"4871_CR8","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/ki.2014.246","volume":"86","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N et al (2014) Sodium glucose cotransport-2 inhibition and intrarenal ras activity in people with type 1 diabetes. Kidney Int 86(5):1057\u20131058. \n                    https:\/\/doi.org\/10.1038\/ki.2014.246","journal-title":"Kidney Int"},{"issue":"3","key":"4871_CR9","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1001\/jama.2014.6593","volume":"312","author":"WS Klein","year":"2014","unstructured":"Klein WS, Merz CN, Jenkins MR (2014) Guidelines for managing high blood pressure. JAMA 312(3):294\u2013295. \n                    https:\/\/doi.org\/10.1001\/jama.2014.6593","journal-title":"JAMA"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-019-4871-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-019-4871-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-019-4871-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T00:02:46Z","timestamp":1586563366000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-019-4871-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,11]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["4871"],"URL":"https:\/\/doi.org\/10.1007\/s00125-019-4871-8","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"type":"print","value":"0012-186X"},{"type":"electronic","value":"1432-0428"}],"subject":[],"published":{"date-parts":[[2019,4,11]]},"assertion":[{"value":"14 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DZIC has acted as a consultant and received honoraria from Boehringer Ingelheim, Lilly, Merck, Janssen, Sanofi, AbbVie, Mitsubishi-Tanabe Pharma and AstraZeneca and has received research operating funds from Boehringer Ingelheim-Lilly Diabetes Alliance, Merck, AstraZeneca and Janssen. BAP has received grants to his research institute and served on the advisory board for Boehringer Ingelheim. All other authors declare that they have no duality of interest associated with their contribution to this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Duality of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}